Search Results - "Connell, Carol A"

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis by Fleischmann, Roy, Kremer, Joel, Cush, John, Schulze-Koops, Hendrik, Connell, Carol A, Bradley, John D, Gruben, David, Wallenstein, Gene V, Zwillich, Samuel H, Kanik, Keith S

“…In a placebo-controlled trial, monotherapy with tofacitinib, an oral Janus kinase inhibitor, reduced the symptoms and signs of rheumatoid arthritis. Adverse…”
Get full text

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry by Kremer, Joel M., Bingham, Clifton O., Cappelli, Laura C., Greenberg, Jeffrey D., Madsen, Ann M., Geier, Jamie, Rivas, Jose L., Onofrei, Alina M., Barr, Christine J., Pappas, Dimitrios A., Litman, Heather J., Dandreo, Kimberly J., Shapiro, Andrea B., Connell, Carol A., Kavanaugh, Arthur

“…Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates…”
Get full text

Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib by Bird, Paul, Hall, Stephen, Nash, Peter, Connell, Carol A, Kwok, Kenneth, Witcombe, David, Thirunavukkarasu, Krishan

“…ObjectivesTofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). We examined response to tofacitinib 5 or 10 mg two times a day…”
Get full text

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials by Landewé, Robert B M, Connell, Carol A, Bradley, John D, Wilkinson, Bethanie, Gruben, David, Strengholt, Sander, van der Heijde, Désirée

“…The detection of statistically significant reductions in radiographic progression during clinical studies in patients with rheumatoid arthritis (RA) has become…”
Get full text

Fracture in clinical studies of tofacitinib in rheumatoid arthritis by Hansen, Karen E., Mortezavi, Mahta, Nagy, Edward, Wang, Cunshan, Connell, Carol A., Radi, Zaher, Litman, Heather J., Adami, Giovanni, Rossini, Maurizio

“…Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk…”
Get full text

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study by Buch, Maya H, Bhatt, Deepak L, Charles-Schoeman, Christina, Giles, Jon T, Mikuls, Ted, Koch, Gary G, Ytterberg, Steven, Nagy, Edward, Jo, Hyejin, Kwok, Kenneth, Connell, Carol A, Masri, Karim Richard, Yndestad, Arne

“…ObjectivesCompare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid…”
Get full text

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis by Ytterberg, Steven R, Bhatt, Deepak L, Mikuls, Ted R, Koch, Gary G, Fleischmann, Roy, Rivas, Jose L, Germino, Rebecca, Menon, Sujatha, Sun, Yanhui, Wang, Cunshan, Shapiro, Andrea B, Kanik, Keith S, Connell, Carol A

“…In this randomized noninferiority trial involving patients with rheumatoid arthritis, cardiovascular events and cancers occurred more frequently with…”
Get full text

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance by Charles-Schoeman, Christina, Buch, Maya H, Dougados, Maxime, Bhatt, Deepak L, Giles, Jon T, Ytterberg, Steven R, Koch, Gary G, Vranic, Ivana, Wu, Joseph, Wang, Cunshan, Kwok, Kenneth, Menon, Sujatha, Rivas, Jose L, Yndestad, Arne, Connell, Carol A, Szekanecz, Zoltan

“…Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid…”
Get more information

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial by Curtis, Jeffrey R, Yamaoka, Kunihiro, Chen, Yi-Hsing, Bhatt, Deepak L, Gunay, Levent M, Sugiyama, Naonobu, Connell, Carol A, Wang, Cunshan, Wu, Joseph, Menon, Sujatha, Vranic, Ivana, Gómez-Reino, Juan J

“…To evaluate malignancies and their associations with baseline risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor…”
Get more information

Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study by van der Heijde, Désirée, Tanaka, Yoshiya, Fleischmann, Roy, Keystone, Edward, Kremer, Joel, Zerbini, Cristiano, Cardiel, Mario H., Cohen, Stanley, Nash, Peter, Song, Yeong‐Wook, Tegzová, Dana, Wyman, Bradley T., Gruben, David, Benda, Birgitta, Wallenstein, Gene, Krishnaswami, Sriram, Zwillich, Samuel H., Bradley, John D., Connell, Carol A.

“…Objective The purpose of this 24‐month phase III study was to examine structural preservation with tofacitinib in patients with rheumatoid arthritis (RA) with…”
Get full text

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply by Ytterberg, Steven R, Bhatt, Deepak L, Connell, Carol A

Get full text

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial by Balanescu, Andra-Rodica, Citera, Gustavo, Pascual-Ramos, Virginia, Bhatt, Deepak L, Connell, Carol A, Gold, David, Chen, All-Shine, Sawyerr, Gosford, Shapiro, Andrea B, Pope, Janet E, Schulze-Koops, Hendrik

“…To characterise infections in patients with rheumatoid arthritis (RA) in ORAL Surveillance. In this open-label, randomised controlled trial, patients with RA…”
Get more information

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs by Fleischmann, Roy, Cutolo, Maurizio, Genovese, Mark C., Lee, Eun Bong, Kanik, Keith S., Sadis, Seth, Connell, Carol A., Gruben, David, Krishnaswami, Sriram, Wallenstein, Gene, Wilkinson, Bethanie E., Zwillich, Samuel H.

“…Objective To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP‐690,550) or adalimumab monotherapy with placebo for the…”
Get full text

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone by Kremer, Joel M., Cohen, Stanley, Wilkinson, Bethanie E., Connell, Carol A., French, Jonathan L., Gomez-Reino, Juan, Gruben, David, Kanik, Keith S., Krishnaswami, Sriram, Pascual-Ramos, Virginia, Wallenstein, Gene, Zwillich, Samuel H.

“…Objective To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP‐690,550) with placebo for the treatment of active rheumatoid…”
Get full text

Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry by Winthrop, Kevin L, Citera, Gustavo, Gold, David, Henrohn, Dan, Connell, Carol A, Shapiro, Andrea B, Shi, Harry, Onofrei, Alina M, Pappas, Dimitrios A, Schulze-Koops, Hendrik

Get more information

A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population by Kivitz, Alan J., Cohen, Stanley, Keystone, Edward, van Vollenhoven, Ronald F., Haraoui, Boulos, Kaine, Jeffrey, Fan, Haiyun, Connell, Carol A., Bananis, Eustratios, Takiya, Liza, Fleischmann, Roy

“…This post-hoc, pooled analysis of Phase 3 studies of tofacitinib examined the safety of tofacitinib 5 and 10 mg twice daily (BID) when used as monotherapy…”
Get full text

Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients by Charles‐Schoeman, Christina, Fleischmann, Roy, Mysler, Eduardo, Greenwald, Maria, Ytterberg, Steven R., Koch, Gary G., Bhatt, Deepak L., Wang, Cunshan, Mikuls, Ted R., Chen, All‐shine, Connell, Carol A., Woolcott, John C., Menon, Sujatha, Chen, Yan, Lee, Kristen, Szekanecz, Zoltán

“…Objective The ORAL Surveillance trial found a dose‐dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib…”
Get full text

Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study by McInnes, Iain B, Kim, Ho-Youn, Lee, Sang-Heon, Mandel, David, Song, Yeong-Wook, Connell, Carol A, Luo, Zhen, Brosnan, M Julia, Zuckerman, Andrea, Zwillich, Samuel H, Bradley, John D

“…To evaluate the efficacy and safety of atorvastatin versus placebo in modifying lipids in patients with rheumatoid arthritis (RA) receiving the oral Janus…”
Get more information

Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals by Wang, Xiaoxing, Dowty, Martin E., Wouters, Ann, Tatulych, Svitlana, Connell, Carol A., Le, Vu H., Tripathy, Sakambari, O’Gorman, Melissa T., Winton, Jennifer A., Yin, Natalie, Valdez, Hernan, Malhotra, Bimal K.

“…Background and Objective Abrocitinib is a Janus kinase 1-selective inhibitor for the treatment of moderate-to-severe atopic dermatitis. Abrocitinib is…”
Get full text

Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies by Charles-Schoeman, Christina, van der Heijde, Désirée, Burmester, Gerd R, Nash, Peter, Zerbini, Cristiano A F, Connell, Carol A, Fan, Haiyun, Kwok, Kenneth, Bananis, Eustratios, Fleischmann, Roy

“…Tofacitinib has been investigated for the treatment of rheumatoid arthritis (RA) in phase III studies in which concomitant glucocorticoids (GC) were allowed…”
Get full text